EUVIMEDSkopri EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Time to use the right classification to predict the severity of checkpoint inhibitor‐induced liver injury, as assessed for causality using the updated RUCAM

Lina Hountondji iD, Stéphanie Faure, Pascale Palassin, Philine Witkowski Durand Viel, Marie Dupuy, Dominique Larrey, Anouck Lamoureux, Cyrille Coustal, Dimitri Pureur, Candice Lesage, Éric Assenat, Benjamin Rivière and 5 more

Alimentary Pharmacology & Therapeutics · 2024-12 · 60 (11-12) · 1561-1572

DOI: 10.1111/apt.18276 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, published online on 2024-09-24. Written by Lina Hountondji and 16 co-authors. Institution: Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France. Major MEDLINE topics: Chemical and Drug Induced Liver Injury, Immune Checkpoint Inhibitors, Severity of Illness Index. Cited 22 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Aims While immune checkpoint inhibitors (ICIs) are revolutionising cancer therapy, checkpoint inhibitor‐induced liver injury is a significant immune‐related side effect of this immunotherapy. This study focuses on the severity classifications and characteristics of patients with checkpoint inhibitor‐induced hepatitis.

Methods

A retrospective analysis of patients with severe Checkpoint Inhibitor‐induced hepatitis grade 3 and 4 according to the recommended Common Terminology Criteria for Adverse Events (CTCAE) classification was conducted. Data on clinicobiological characteristics, treatment and outcomes were collected from 3 university hospitals, and causality was assessed by using the updated Roussel Uclaf Causality Assessment Method. The severity of hepatitis was assessed using the Model for End‐stage Liver Disease score, the Drug‐Induced Liver Injury Network, and the Drug‐Induced Liver Injury International Expert Working Group classifications.

Results

We retrospectively included 100 patients presenting various hepatitis patterns with a median time to onset of 20 days after checkpoint inhibitors. Severity grading varied significantly among the classifications used. A lower incidence of severe cases was observed when using the Drug‐Induced Liver Injury classifications instead of the recommended CCTCAE classification, and this was correlated with outcomes.

Conclusions

This retrospective study challenges the efficacy of the CTCAE classification in defining the severity of Checkpoint Inhibitor‐induced hepatitis and suggests that the traditional hepatology‐focused scores may be more relevant. The CTCAE classification is inconsistent and gives equal weight to jaundice and elevated transaminases, which leads to steroid overtreatment and limits the rechallenge of ICIs.

Subjects

MeSH terms (MEDLINE)

Chemical and Drug Induced Liver InjuryImmune Checkpoint InhibitorsSeverity of Illness IndexHumansRetrospective StudiesMaleFemaleMiddle AgedAgedAdultNeoplasmsAged, 80 and over

Substances

Immune Checkpoint Inhibitors

Authors and institutions

  • Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.
  • Department of Medical Pharmacology and Toxicology, Lapeyronie Hospital, Montpellier University Hospital, Montpellier, France.
  • Department of Medical Oncology, Montpellier Cancer Institute, Montpellier University Hospital, Montpellier, France.
  • Internal Medicine, Beziers Hospital, Béziers, France.
  • Department of Oncology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.
  • REFHEPS, Montpellier, France.

ORCID profiles: Lina Hountondji, Georges-Philippe Pageaux

Cite

APA

Hountondji, L., Faure, S., Palassin, P., Viel, P. W. D., Dupuy, M., Larrey, D., Lamoureux, A., Coustal, C., Pureur, D., Lesage, C., Assenat, É., Rivière, B., Faillie, J. L., Quantin, X., Pageaux, G. P., Maria, A. T. J., & Meunier, L. (2024). Time to use the right classification to predict the severity of checkpoint inhibitor‐induced liver injury, as assessed for causality using the updated RUCAM. Alimentary Pharmacology & Therapeutics, 60(11-12), 1561-1572. https://doi.org/10.1111/apt.18276

Vancouver

Hountondji L, Faure S, Palassin P, Viel PWD, Dupuy M, Larrey D, et al. Time to use the right classification to predict the severity of checkpoint inhibitor‐induced liver injury, as assessed for causality using the updated RUCAM. Alimentary Pharmacology & Therapeutics. 2024;60(11-12):1561-1572. doi:10.1111/apt.18276

BibTeX
@article{Hountondji2024,
  author = {Hountondji, Lina and Faure, Stéphanie and Palassin, Pascale and Viel, Philine Witkowski Durand and Dupuy, Marie and Larrey, Dominique and Lamoureux, Anouck and Coustal, Cyrille and Pureur, Dimitri and Lesage, Candice and Assenat, Éric and Rivière, Benjamin and Faillie, Jean-Luc and Quantin, Xavier and Pageaux, Georges-Philippe and Maria, Alexandre Thibault Jacques and Meunier, Lucy},
  title = {Time to use the right classification to predict the severity of checkpoint inhibitor‐induced liver injury, as assessed for causality using the updated RUCAM},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {60},
  number = {11-12},
  pages = {1561--1572},
  doi = {10.1111/apt.18276}
}
Start for free →